Patents by Inventor Johan Bylund

Johan Bylund has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bis(sulfonamide) derivatives and their use as mPGES inhibitors
    Patent number: 10227296
    Abstract: The present invention relates to bis(sulfonamide) compounds and pharmaceutically acceptable salts thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as a medicament for the treatment and/or prevention of a disease, disorder or condition in which modulation of microsomal prostaglandin E synthase-1 activity is beneficial, such as pain, inflammation and cancer.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: March 12, 2019
    Assignee: Arcturum Real Estate AB
    Inventors: Peter Söderman, Mats A. Svensson, Annika Kers, Liselott Öhberg, Katharina Högdin, Andreas Hettman, Jesper Hallberg, Maria Ek, Johan Bylund, Johan Nord
  • RESPIRATORY SYNCYTIAL VIRUS INHIBITORS
    Publication number: 20190002436
    Abstract: Compounds of Formula (I): (Formula I), wherein Z1 is NR1A, CHR1A, CR1BR1B; one of Z2 and Z3 is CH or CR1A?, the other is N, CH or CR1A?; n is 0, 1 or 2; q is 0, 1 or 2; R1A, R1A?, R1B, R2, and R3 are as defined herein, their use as inhibitors of RSV and related aspects.
    Type: Application
    Filed: July 28, 2016
    Publication date: January 3, 2019
    Inventors: Susana AYESA, Karolina ERSMARK, Gennadiy KALAYANOV, Marie LEIJONMARCK, Lourdes Salvador ODEN, Hans WESTERLIND, Horst WAHLING, Megan BERTRAND, Christian BROCHU, Elise GHIRO, Cyrille KUHN, Claudio STURINO, Johan BYLUND, Fernando SEHGELMEBLE, Stina LUNDGREN
  • Bis(sulfonamide) derivatives and their use as mPGES inhibitors
    Patent number: 10081614
    Abstract: The present invention relates to bis(sulfonamide) compounds and pharmaceutically acceptable salts thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as a medicament for the treatment and/or prevention of a disease, disorder or condition in which modulation of microsomal prostaglandin E synthase-1 activity is beneficial, such as pain, inflammation and cancer.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: September 25, 2018
    Assignee: ACTURUM REAL ESTATE AB
    Inventors: Peter Söderman, Mats A. Svensson, Annika Kers, Liselott Öhberg, Katharina Högdin, Andreas Hettman, Jesper Hallberg, Maria Ek, Johan Bylund, Johan Nord
  • BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS
    Publication number: 20180002278
    Abstract: The present invention relates to bis(sulfonamide) compounds and pharmaceutically acceptable salts thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as a medicament for the treatment and/or prevention of a disease, disorder or condition in which modulation of microsomal prostaglandin E synthase-1 activity is beneficial, such as pain, inflammation and cancer.
    Type: Application
    Filed: November 24, 2015
    Publication date: January 4, 2018
    Inventors: Peter SÖDERMAN, Mats A. SVENSSON, Annika KERS, Liselott ÖHBERG, Katharina HÖGDIN, Andreas HETTMAN, Jesper HALLBERG, Maria EK, Johan BYLUND, Johan NORD
  • BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS
    Publication number: 20170313672
    Abstract: The present invention relates to bis(sulfonamide) compounds and pharmaceutically acceptable salts thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as a medicament for the treatment and/or prevention of a disease, disorder or condition in which modulation of microsomal prostaglandin E synthase-1 activity is beneficial, such as pain, inflammation and cancer.
    Type: Application
    Filed: November 24, 2015
    Publication date: November 2, 2017
    Inventors: Peter SÖDERMAN, Mats A. SVENSSON, Annika KERS, Liselott ÖHBERG, Katharina HÖGDIN, Andreas HETTMAN, Jesper HALLBERG, Maria EK, Johan BYLUND, Johan NORD
  • Bis-(sulfonylamino) derivatives for use in therapy
    Patent number: 9145380
    Abstract: The invention provides compounds of formula (I) wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: September 29, 2015
    Assignee: Astrazeneca AB
    Inventors: Johan Bylund, Maria E Ek, Ylva Gravenfors, Gunnar Nordvall, Alexander Minidis, Karl S. A Vallin, Jenny Viklund, Jörg Holenz, Stefan Von Berg, Daniel Sohn
  • Bis-(Sulfonylamino) Derivatives in Therapy 066
    Publication number: 20110021540
    Abstract: The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
    Type: Application
    Filed: November 14, 2008
    Publication date: January 27, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Johan Bylund, Maria Ek, Jorg Holenz, Martin H. Johansson, Annika Kers, Katja Narhi, Gunnar Nordvall, Liselotte Ohberg, Daniel Sohn, Jenny Viklund, Stefan Von Berg
  • Bis-(Sulfonylamino) derivatives for use in therapy
    Publication number: 20100331321
    Abstract: The invention provides compounds of formula (I) wherein R1,R3,L1,L2,G1,G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
    Type: Application
    Filed: December 18, 2008
    Publication date: December 30, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Johan Bylund, Maria E. Ek, Ylva Gravenfors, Jorg Holenz, Alexander Minidis, Gunnar Nordvall, Daniel Sohn, Karl S.A. Vallin, Jenny Viklund, Stefan Von Berg
  • Bis-(Sulfonylamino) Derivatives in Therapy
    Publication number: 20100292279
    Abstract: The invention provides compounds of formula wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
    Type: Application
    Filed: May 12, 2010
    Publication date: November 18, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Johan Bylund, Maria E. Ek, Jörg Holenz, Annika Kers, Liselotte Öhberg
  • Bis-(Sulfonylamino) Derivatives in Therapy 066
    Publication number: 20090281138
    Abstract: The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
    Type: Application
    Filed: November 14, 2008
    Publication date: November 12, 2009
    Applicant: AstraZeneca AB
    Inventors: Johan Bylund, Marie E. Ek, Annika Kers, Gunnar Nordvall, Liselotte Ohberg, Jenny Viklund, Stefan Von Berg, Jorg Holenz, Katja Narhi, Daniel Sohn, Martin H. Johansson
  • Bis-(Sulfonylamino) Derivatives in Therapy 205
    Publication number: 20090163586
    Abstract: The invention provides compounds of formula (I) wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
    Type: Application
    Filed: December 17, 2008
    Publication date: June 25, 2009
    Applicant: AstraZeneca AB
    Inventors: Johan Bylund, Maria E. Ek, Ylva Gravenfors, Jorg Holenz, Alexander Minidis, Gunnar Nordvall, Daniel Sohn, Karl S.A. Vallin, Jenny Viklund, Stefan Von Berg
  • Bis-(Sulfonylamino) Derivatives in Therapy 065
    Publication number: 20090131468
    Abstract: The invention provides compounds of formula wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
    Type: Application
    Filed: November 14, 2008
    Publication date: May 21, 2009
    Applicant: AstraZeneca AB
    Inventors: Johan Bylund, Marie E. Ek, Annika Kers, Gunnar Nordvall, Liselotte Ohberg, Jenny Viklund, Stefan Von Berg, Jorg Holenz, Katja Narhi, Daniel Sohn, Martin H. Johansson